Slide 1: Q3 2023 Update Conference Call
NYSE American: AIM. aimimmuno.com. AIM ImmunoTech Q3 2023 Update ‘onference Call _ November 15, 2023
Slide 2: Forward Looking Statements
Forward Looking ' Statements ’ reflect events or circumstances that occur after the date hereof. We are in various ymmaresdehsery src gg gaara our cur e her Ampligen® willbe effectiv Ampligen® will be effica lack of regulatory approval(s), lack of study nical studies will be successful or yield any
Slide 3: Qaim
Qaim
Slide 4: Continued Execution Across Clinical Development Programs
Continued Execution Across Clinical Development Programs Well Positioned to Achieve Multiple Value-Driving Milestones Throughout the Remainder of 2023 and 2024 iii.
Slide 5: Lead Program Ampligen (rintatolimod)
Lead Program Ampligen® (rintatolimod) immu
Slide 6: Broad Pipeline Across Multiple Unmet Needs
Broad Pipeline Across Multiple Unmet Needs Priority Development Programs ion: Locally Advanced Ampligen* Following C ap270— , ; AMP-271 Pancreatic Adenocarcinoma —_FOLFIRINOX oO Patient Recruitment Underway Metastatic Pancreatic Ductal Ampligen and Adenocarcinoma Durvalumab DURIPAN' Study Launch Exp
Slide 7: Clinical Update
Qaim Clinical Update Continued Ai DeVelopmen (ou
Slide 8: AMP-270 Locally Advanced Pancreatic Cancer
AMP-270 = Locally Advanced Pancreatic Cancer Open Sites University of Nebraska Fah Wc @ Virginia Mason @@ Franciscan Health COLLEGE OF MEDICINE Expect Erasmus MC to Expect as many as 12 Additional Sites Open for Recruitment in Q4 Opened in First Half of 2024 am
Slide 9: Metastatic Triple-Negative Breast Cancer
Metastatic Triple-Negative Breast Cancer Manuscript Published in The Journal for ImmunoTherapy of Cancer: “Systemic Infusion of TLR3-Ligand and IFNa in Breast Cancer Patients Reprograms Local Tumor Microenvironments for Selective CTL Influx” Summary: * Patients with metastatic Triple Negative breast
Slide 10: Early-Stage Triple Negative Breast Cancer
Early-Stage Triple Negative Breast Cancer Study results posted to ClinicalTrials.gov NCT04081389 Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery NCT04081389
Slide 11: DURIPANC: Metastatic Pancreatic Ductal Adenocarcinoma
DURIPANC: Metastatic Pancreatic Ductal Adenocarcinoma Sponsored Collaborative Erasmus MC Clinical Research Agreement AstraZeneca a Initiate Recruitment Vv Received QP Declaration and import Projected approval for Ampligen® Q4 2023 v Ampligen® to be shipped to EU for final QP release v Multiple patie
Slide 12: Platinum-Sensitive Advanced Recurrent Ovarian Cancer
Platinum-Sensitive Advanced Csitc > Recurrent Ovarian Cancer sy tenn tne | Phase2— Encouraging Translational Data from Ongoing Phase 2 Trial Stat Protocol-Planned Interim iad Results Q3 2023 od oT ‘Ampligen in Fi i rh tit fi Study Drug Pe TTRUDAT bid H d q = = errr rs aerrer Primary Objective Respon
Slide 13: Platinum-Sensitive Advanced Recurrent Ovarian Cancer
Platinum-Sensitive Advanced Recurrent Ovarian Cancer Sciey fo _ 767 DE genes before and after chemoimmunotherapy - GSEA 1434 DE genes show “chronic” response during treatment analysis shows enrichment in IFN «and IFN y response Acute (log2fold) Chronic (log2fold) i 1 I CXCL10 4.677805 ‘CXCLO 1.74752
Slide 14: AMP-518 Post-COVID Conditions
AMP-518 Ampligen® as a Potential Treatment of Post-COVID Conditions Fully Enrolled with Top-Line Data Expected in Q1 2024 ‘Long Haulers’ Share Extremely Similar Phase 2 Study _ Post-COVID Condition of Fatigue Characteristics to ME/CFS Completed Enrollment; i) a SERB Topline Data expected as Early as
Slide 15: Qaim
15 Qaim
Slide 16: Expecting Multiple Value Driving Milestones
Expecting Multiple Value Driving Milestones Focused on Delivering Results San Study Collaborators AstraZeneca? © MERCK ch NY SlteeFfcancencenten
Slide 17: Financial Snapshot
Financial Snapshot v am Cash Position Expected to Fund Operations Through Multiple Key Milestones Cash, Cash Equivalents and Marketable Securities of $22.4 million as of September 30, 2023 Research and Development Expenses for the three months ended of September 30, 2023, were $2.7 million, compared
Slide 18: Achieving clinical and regulatory milestones
. >) Achieving clinical and regulatory milestones Driving strategy (>) for industry licensing / M&A nstitutional in